Merck Reaches Nearly $6 Billion Deal for Cancer Biotech Terns

Date:




The drugmaker has been seeking to bolster its pipeline as its top-selling drug, Keytruda, is set to lose patent protection.



Source link

Share post:

Subscribe

spot_imgspot_img

Popular

More like this
Related